GM-CSF appeared to be a very attractive option in preclinical investigations because it aids in attracting DCs to the injection site, fosters DCs’ maturation, and facilitates antigen presentation, all of which can boost the cancer-specific immune response [102]. Here, CSF2 is linked to cancer.